Pemvidutide Protocol — Complete Dosing & Administration Guide

Dosing

How muchdo I take?

Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.

Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.

Starting Dose

1.2 mg

Frequency

Once weekly

Duration

48 weeks

Lowest dose studied; given at full strength from week 1 with no titration. Produced ~10% weight loss at 48 weeks in the MOMENTUM Phase 2 obesity trial [6] and is the lower MASH dose in the IMPACT Phase 2b trial [7].

Standard Dose

1.8 mg

Mid dose, started at full strength with no titration; ~11% weight loss at 48 weeks (MOMENTUM) [6] and the higher MASH dose in IMPACT [7].

Advanced Dose

2.4 mg

Highest dose; reached via a 4-week titration in MOMENTUM, where it produced 15.6% weight loss at 48 weeks [6].

Timing

Best time to take

Administer Pemvidutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.

With food?

Pemvidutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.

If stacking

Pemvidutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting Your Dose

Increase if

+You've tolerated the current dose for the recommended period without significant side effects

+Therapeutic goals haven't been met at the current dose level

+Your healthcare provider recommends dose escalation based on your response

+Lab work or clinical assessments support a higher dose

Decrease if

-Side effects are bothersome or impacting daily life despite management strategies

-You experience any signs of an adverse reaction

-Lab results indicate the need for dose reduction

-Your healthcare provider recommends a lower dose based on your response

Signs of right dose

✓Therapeutic goals being met with minimal side effects

✓Stable and consistent response to treatment

✓Lab values or clinical markers trending in the right direction

✓Good tolerance with manageable or absent side effects

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

The weight is on the label

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Administration

How do Iuse it?

Reconstitution

What you need

•Pemvidutide vial (lyophilized powder or solution)

•Bacteriostatic water or sterile sodium chloride for reconstitution

•Alcohol swabs for cleaning vial tops and injection sites

•Appropriately sized syringes with fine-gauge needles (27-30 gauge)

•Sharps disposal container

Example

Add the recommended volume of bacteriostatic water to the Pemvidutide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.

Your dose of Pemvidutide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

•Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection

•Front of thighs—middle to upper portion of the outer leg

•Back of upper arm—outer area (may need assistance from another person)

Technique

1.Wash your hands thoroughly with soap and water before handling supplies

2.Clean the injection site with an alcohol swab and let it air dry completely

3.Pinch a fold of skin at the chosen injection site

4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)

5.Inject the medication slowly and steadily over 5-10 seconds

6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab

7.Rotate injection sites to prevent tissue irritation or lipodystrophy

8.Dispose of the needle safely in a sharps container—never recap or reuse needles

Storage

Before reconstitution

Store Pemvidutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Pemvidutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

Solution appears cloudy, discolored, or contains visible particles (should be clear)

Product has been exposed to temperatures outside the recommended storage range

Product has been frozen (unless specifically designed for freeze-thaw stability)

Expiration date has passed or reconstituted solution has exceeded its use-by date

Unusual odor, color change, or visible contamination

Sample Daily Schedule

As prescribed (once daily)

As prescribed by your healthcare provider injection

Site: Subcutaneous injection—rotate sites if applicable

Maintain a consistent schedule for optimal results with Pemvidutide. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is itsafe?

Safety Profile

Pemvidutide (rzenx, Eli Lilly GLP-1/GCG dual agonist) completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.

Phase IIb RCTs (n=500+) demonstrate dual GLP-1R/GCR mechanism through glucose-dependent hyperglycemia correction and weight loss up to 18% over 52 weeks. Fasting lipid improvements with 20-30% triglyceride reductions and 10-15% LDL decreases measured via standard lipid panels. Mechanistic studies via indirect calorimetry show increased energy expenditure; pancreatic imaging via MRI shows no structural changes.

Common Side Effects

Experienced by some users

Nausea

Most commonly reported adverse event, generally mild and often resolving within the first few weeks of treatment.

Management: Eat smaller, more frequent meals. Avoid high-fat or greasy foods. Stay well hydrated.

Diarrhea

Mild to moderate gastrointestinal disturbance occurring in a meaningful proportion of trial participants.

Management: Maintain hydration, consider bland diet temporarily, and consult prescriber if persistent beyond 2 weeks.

Headache

Reported in clinical trials, typically mild and self-resolving without intervention.

Management: Standard analgesics as needed. Ensure adequate hydration and regular meals.

Less Common

•Vomiting

•Decreased Appetite

These typically resolve with continued use or dose adjustment.

Stop and Seek Help If

×Severe or worsening side effects that don't improve with dose adjustment or supportive care

×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing

×Your healthcare provider recommends discontinuation based on your clinical response

×Development of any new medical condition that may be contraindicated with Pemvidutide

×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)

×Abnormal lab results or clinical markers that suggest adverse effects

Pemvidutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Interactions

With other peptides

✓May be used together under medical guidance.

With medications

!Other GLP-1 Receptor Agonists - Use with caution—discuss with your healthcare provider.

!Sulfonylureas - Use with caution—discuss with your healthcare provider.

!Insulin (without dose adjustment) - Use with caution—discuss with your healthcare provider.

With supplements

✓Multivitamins - Generally safe to take alongside Pemvidutide. Space doses apart if taking oral formulations to ensure optimal absorption.

✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Want the Full Picture?

View the complete Pemvidutide research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.